ChromaDex (CDXC) Competitors

ChromaDex (NASDAQ:CDXC) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, community ranking, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

Does the MarketBeat Community believe in CDXC or IMVT?

ChromaDex received 421 more outperform votes than Immunovant when rated by MarketBeat users. However, 78.11% of users gave Immunovant an outperform vote while only 64.83% of users gave ChromaDex an outperform vote.

Company	Underperform	Outperform
ChromaDex	Outperform Votes 553 64.83%	Underperform Votes 300 35.17%
Immunovant	Outperform Votes 132 78.11%	Underperform Votes 37 21.89%

Which has more risk and volatility, CDXC or IMVT?

ChromaDex has a beta of 2.21, indicating that its share price is 121% more volatile than the S&P 500. Comparatively, Immunovant has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500.

Does the media favor CDXC or IMVT?

In the previous week, Immunovant had 12 more articles in the media than ChromaDex. MarketBeat recorded 13 mentions for Immunovant and 1 mentions for ChromaDex. Immunovant's average media sentiment score of 1.16 beat ChromaDex's score of 0.00 indicating that Immunovant is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ChromaDex	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immunovant	9 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts rate CDXC or IMVT?

ChromaDex presently has a consensus target price of $9.03, suggesting a potential upside of 0.00%. Immunovant has a consensus target price of $41.00, suggesting a potential upside of 165.03%. Given Immunovant's higher possible upside, analysts clearly believe Immunovant is more favorable than ChromaDex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ChromaDex	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Immunovant	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	3.00

Is CDXC or IMVT more profitable?

ChromaDex has a net margin of 1.62% compared to Immunovant's net margin of 0.00%. ChromaDex's return on equity of 4.85% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ChromaDex	1.62%	4.85%	2.70%
Immunovant	N/A	-77.94%	-69.82%

Do insiders and institutionals hold more shares of CDXC or IMVT?

15.4% of ChromaDex shares are held by institutional investors. Comparatively, 47.1% of Immunovant shares are held by institutional investors. 9.6% of ChromaDex shares are held by insiders. Comparatively, 5.9% of Immunovant shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Which has stronger earnings & valuation, CDXC or IMVT?

ChromaDex has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than ChromaDex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ChromaDex	$99.60M	0.00	-$4.94M	$0.10	N/A
Immunovant	N/A	N/A	-$259.34M	-$2.62	-5.90

Summary

ChromaDex beats Immunovant on 10 of the 17 factors compared between the two stocks.